NCT01003808View on ClinicalTrials.gov

Safety Study of a Recombinant Protein Vaccine to Treat Esophageal Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

March 31, 2012

Study Completion Date

December 31, 2012

Conditions
Esophageal Cancer
Interventions
BIOLOGICAL

IMF-001

100 or 200 mcg, subcutaneously every 2 weeks. Number of Injections: 6 times. (The treatment may be continued if it is beneficial to the subject).

Trial Locations (4)

464-8681

Aichi Cancer Center Hospital, Nagoya

514-8507

Mie University Hospital, Tsu

530-8480

Kitano Hospital, Kitano Hospital

565-0871

Osaka University Hospital, Suita

Sponsors
All Listed Sponsors
lead

ImmunoFrontier, Inc.

INDUSTRY